Results 201 to 210 of about 5,221,373 (330)
Gender-specific motivation for training in sexual history. [PDF]
Platzer N +6 more
europepmc +1 more source
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris +10 more
wiley +1 more source
Self-allocation bias in performance-based cooperative decisions is driven by self-interest rather than distorted performance encoding. [PDF]
Zhang S, Yong X, Ma Y, Korn CW.
europepmc +1 more source
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Changes in Italian Nurses' Genetic Knowledge and Perceptions Over a Decade. [PDF]
Godino L, Magi CE, Ricco M, Turchetti D.
europepmc +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Dense retrieval and reranking for referenced provisions in electric power audit systems. [PDF]
Meng Q +6 more
europepmc +1 more source
Ultra-compact binaries: relevance and role of Utrecht [PDF]
G. Nelemans, L. M. van Haaften
openalex +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source

